Quantumzyme Corp. (OTC: QTZM), a biotransformation company focused on sustainable pharmaceutical manufacturing, provided a corporate update on January 26, 2026, detailing its 2025 achievements and strategic priorities for 2026. The company, which is pursuing a name change to Quantum Genesis AI Corp., emphasized its expanding focus on artificial intelligence and computational methods to enhance enzyme research and development.
During 2025, Quantumzyme advanced its regulatory reporting and disclosure practices, supporting transparency for shareholders. The company progressed its research and development efforts in enzyme engineering and biocatalytic processes, targeting pharmaceutical and specialty chemical applications. These activities remain in the research and evaluation stage. The company also announced the publication of U.S. and international patent applications related to its enzymatic processes, though no assurance exists that patents will be granted. Corporate communications were updated to better describe its business focus and long-term objectives.
A key development in 2025 was Quantumzyme's expansion into artificial intelligence and computational research. The company evaluated machine learning techniques and computational modeling to support enzyme discovery, structure-function analysis, and research prioritization. These AI initiatives are intended to complement laboratory research by improving experimental design and data analysis efficiency. The company believes integrating computational methods may guide future development, but these efforts remain exploratory and subject to technical and financial limitations.
In late 2025, Quantumzyme's Board of Directors approved a proposal to change the company's legal name to Quantum Genesis AI Corp. and seek a corresponding trading symbol change. The proposed name reflects a greater emphasis on computational and data-driven approaches. The company has submitted required documentation, and the changes are subject to FINRA approval, expected during the first quarter of 2026.
For 2026, Quantumzyme outlined strategic priorities including continued research and evaluation of enzyme candidates and biocatalytic pathways, refining computational modeling and AI tools, exploring potential partnerships or licensing opportunities with pharmaceutical and chemical industry participants, increasing visibility through scientific forums and investor communications, and assessing long-term corporate objectives such as reporting status and capital planning. The company cautioned that these objectives are subject to risks including technical challenges, capital availability, and market conditions.
More information is available at www.quantumzymecorp.com and the company's profile at www.otcmarkets.com/stock/QTZM.
